Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 280
- Registration Number
- NCT06598631
- Locations
- 🇺🇸
Eastern Nephrology Associates- New Bern Office Loc. 1, New Bern, North Carolina, United States
🇺🇸Diabetes and Metabolism Associates, APMC, Metairie, Louisiana, United States
🇺🇸Elite Clinical Research Center, Flint, Michigan, United States
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06603571
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇦🇷Centro Médico Viamonte, Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06598943
- Locations
- 🇺🇸
Southern California Research Center, Inc., Coronado, California, United States
🇺🇸Southern California GI and Liver Centers (SCLC), Coronado, California, United States
🇺🇸Orlando Health Digestive Health Institute, Orlando, Florida, United States
A Study of LY4065967 in Healthy Japanese Participants
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT06594159
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸City of Hope Medical Group, South Pasadena, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588296
- Locations
- 🇺🇸
Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
🇺🇸Research Physicians Network, LLC, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Katy, Texas, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588283
- Locations
- 🇺🇸
NeoClinical Research, Hialeah, Florida, United States
🇺🇸Skin Care Research, Hollywood, Florida, United States
🇺🇸Encore Medical Research, Hollywood, Florida, United States
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06584916
- Locations
- 🇺🇸
Cahaba Research, Birmingham, Alabama, United States
🇺🇸Cahaba Research - Pelham, Pelham, Alabama, United States
🇺🇸Southern California Dermatology, Inc., Santa Ana, California, United States
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06568042
- Locations
- 🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Accel Research Sites - St. Pete-Largo Clinical Research Unit, Largo, Florida, United States
🇨🇦Dawson Clinical Research Inc., Guelph, Ontario, Canada
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3060
- Registration Number
- NCT06566170
- Locations
- 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States